Leasing ex-Genzyme HQ
Boston Herald | By Donna Goodison
November 23, 2016
Drug maker Shire PLC will expand its Kendall Square footprint in Cambridge by leasing the building known as the Genzyme Center to create a rare disease “innovation hub.”
The company signed a 12-year lease for the 343,000-square-foot building at 500 Kendall St., which is next to the 206,000-square-foot building it has occupied at 650 East Kendall St. since 2015.
The buildings will be a “cross-disciplinary” campus for Shire that will include research, clinical development, medical affairs and business development teams, the Dublin-based company said. Shire focuses on rare diseases and specialized conditions including ADHD, bleeding disorders, dry eye disease, Gaucher disease, Hunter syndrome, hypoparathyroidism, pancreatic cancer and short bowel syndrome.
“By expanding our presence in Cambridge, with its close proximity to best-in-class hospitals, research institutions, universities and a thriving biotechnology community, we will strengthen our ties with the early innovators around us to shape the next generation of breakthrough therapies for patients with high unmet needs,” CEO Flemming Ornskov said.